688180 君实生物
2026/03 - 三个月
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额57,849(519,568)(1,433,841)(2,004,982)(1,776,201)
投资活动产生之现金流量净额(541,365)(1,580,711)(892,782)(933,191)(437,213)
筹资活动产生之现金流量净额1,792,3492,229,3061,023,146711,8284,613,478
汇率变动对现金及现金等价物的影响(12,144)(21,707)12,0157,55192,266
现金及现金等价物净增加/(减少)1,296,689107,321(1,291,463)(2,218,794)2,492,331
期初现金及现金等价物余额2,594,0002,486,6793,778,1425,996,9363,504,605
期末现金及现金等价物余额3,890,6882,594,0002,486,6793,778,1425,996,936